Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice

Michal Chovanec, Costantine Albany, Michal Mego, Rodolfo Montironi, Alessia Cimadamore, Liang Cheng

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Testicular germ cell tumors are unique among solid cancers. Historically, this disease was deadly if progressed beyond the stage I. The implementation of cisplatin-based chemotherapy regimens has drastically changed the clinical outcome of metastatic testicular cancer. Several biomarkers were established to refine the prognosis by International Germ Cell Collaborative Group in 1997. Among these, the most significant were primary tumor site; metastatic sites, such as non-pulmonary visceral metastases; and the amplitude of serum tumor markers α-fetoprotein, β-chorionic gonadotropin, and lactate dehydrogenase. Since then, oncology has experienced discoveries of various molecular biomarkers to further refine the prognosis and treatment of malignancies. However, the ability to predict the prognosis and treatment response in germ cell tumors did not improve for many years. Clinical trials with novel targeting agents that were conducted in refractory germ cell tumor patients have proven to have negative outcomes. With the recent advances and developments, novel biomarkers emerge in the field of germ cell tumor oncology. This review article aims to summarize the current knowledge in the research of novel prognostic biomarkers in testicular germ cell tumors.

Original languageEnglish (US)
Article number571
JournalFrontiers in Oncology
Volume8
Issue numberNOV
DOIs
StatePublished - Jan 1 2018

Fingerprint

Biomarkers
Germ Cell and Embryonal Neoplasms
Fetal Proteins
Neoplasms
Testicular Neoplasms
Chorionic Gonadotropin
Tumor Biomarkers
L-Lactate Dehydrogenase
Germ Cells
Cisplatin
Testicular Germ Cell Tumor
Clinical Trials
Neoplasm Metastasis
Drug Therapy
Therapeutics
Research

Keywords

  • Biomarkers
  • Liquid biopsy
  • Molecular genetics
  • Testicular germ cell tumors
  • Testis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Emerging prognostic biomarkers in testicular germ cell tumors : Looking beyond established practice. / Chovanec, Michal; Albany, Costantine; Mego, Michal; Montironi, Rodolfo; Cimadamore, Alessia; Cheng, Liang.

In: Frontiers in Oncology, Vol. 8, No. NOV, 571, 01.01.2018.

Research output: Contribution to journalReview article

Chovanec, Michal ; Albany, Costantine ; Mego, Michal ; Montironi, Rodolfo ; Cimadamore, Alessia ; Cheng, Liang. / Emerging prognostic biomarkers in testicular germ cell tumors : Looking beyond established practice. In: Frontiers in Oncology. 2018 ; Vol. 8, No. NOV.
@article{3a71b58167f44357b93e7e8fa7f7c3e2,
title = "Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice",
abstract = "Testicular germ cell tumors are unique among solid cancers. Historically, this disease was deadly if progressed beyond the stage I. The implementation of cisplatin-based chemotherapy regimens has drastically changed the clinical outcome of metastatic testicular cancer. Several biomarkers were established to refine the prognosis by International Germ Cell Collaborative Group in 1997. Among these, the most significant were primary tumor site; metastatic sites, such as non-pulmonary visceral metastases; and the amplitude of serum tumor markers α-fetoprotein, β-chorionic gonadotropin, and lactate dehydrogenase. Since then, oncology has experienced discoveries of various molecular biomarkers to further refine the prognosis and treatment of malignancies. However, the ability to predict the prognosis and treatment response in germ cell tumors did not improve for many years. Clinical trials with novel targeting agents that were conducted in refractory germ cell tumor patients have proven to have negative outcomes. With the recent advances and developments, novel biomarkers emerge in the field of germ cell tumor oncology. This review article aims to summarize the current knowledge in the research of novel prognostic biomarkers in testicular germ cell tumors.",
keywords = "Biomarkers, Liquid biopsy, Molecular genetics, Testicular germ cell tumors, Testis",
author = "Michal Chovanec and Costantine Albany and Michal Mego and Rodolfo Montironi and Alessia Cimadamore and Liang Cheng",
year = "2018",
month = "1",
day = "1",
doi = "10.3389/fonc.2018.00571",
language = "English (US)",
volume = "8",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - Emerging prognostic biomarkers in testicular germ cell tumors

T2 - Looking beyond established practice

AU - Chovanec, Michal

AU - Albany, Costantine

AU - Mego, Michal

AU - Montironi, Rodolfo

AU - Cimadamore, Alessia

AU - Cheng, Liang

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Testicular germ cell tumors are unique among solid cancers. Historically, this disease was deadly if progressed beyond the stage I. The implementation of cisplatin-based chemotherapy regimens has drastically changed the clinical outcome of metastatic testicular cancer. Several biomarkers were established to refine the prognosis by International Germ Cell Collaborative Group in 1997. Among these, the most significant were primary tumor site; metastatic sites, such as non-pulmonary visceral metastases; and the amplitude of serum tumor markers α-fetoprotein, β-chorionic gonadotropin, and lactate dehydrogenase. Since then, oncology has experienced discoveries of various molecular biomarkers to further refine the prognosis and treatment of malignancies. However, the ability to predict the prognosis and treatment response in germ cell tumors did not improve for many years. Clinical trials with novel targeting agents that were conducted in refractory germ cell tumor patients have proven to have negative outcomes. With the recent advances and developments, novel biomarkers emerge in the field of germ cell tumor oncology. This review article aims to summarize the current knowledge in the research of novel prognostic biomarkers in testicular germ cell tumors.

AB - Testicular germ cell tumors are unique among solid cancers. Historically, this disease was deadly if progressed beyond the stage I. The implementation of cisplatin-based chemotherapy regimens has drastically changed the clinical outcome of metastatic testicular cancer. Several biomarkers were established to refine the prognosis by International Germ Cell Collaborative Group in 1997. Among these, the most significant were primary tumor site; metastatic sites, such as non-pulmonary visceral metastases; and the amplitude of serum tumor markers α-fetoprotein, β-chorionic gonadotropin, and lactate dehydrogenase. Since then, oncology has experienced discoveries of various molecular biomarkers to further refine the prognosis and treatment of malignancies. However, the ability to predict the prognosis and treatment response in germ cell tumors did not improve for many years. Clinical trials with novel targeting agents that were conducted in refractory germ cell tumor patients have proven to have negative outcomes. With the recent advances and developments, novel biomarkers emerge in the field of germ cell tumor oncology. This review article aims to summarize the current knowledge in the research of novel prognostic biomarkers in testicular germ cell tumors.

KW - Biomarkers

KW - Liquid biopsy

KW - Molecular genetics

KW - Testicular germ cell tumors

KW - Testis

UR - http://www.scopus.com/inward/record.url?scp=85063291599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063291599&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00571

DO - 10.3389/fonc.2018.00571

M3 - Review article

AN - SCOPUS:85063291599

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - NOV

M1 - 571

ER -